Lakefront Biotherapeutics (GLPGF) Finished Goods (2020 - 2023)

Lakefront Biotherapeutics (GLPGF) has reported Finished Goods for 4 consecutive years, with $6.6 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Finished Goods fell 19.99% year-over-year to $6.6 million in Q4 2023; TTM through Dec 2023 was $6.6 million, a 19.99% decrease from a year earlier, with the FY2023 full-year figure at $6.6 million, down 19.99% from the prior year.
• Finished Goods was $6.6 million for Q4 2023 at Lakefront Biotherapeutics, down from $8.2 million in the prior quarter.
• Over five years, Finished Goods peaked at $8.2 million in Q4 2022 and troughed at $42922.4 in Q4 2020.
• A 4-year average of $5.1 million and a median of $6.1 million in 2023 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods soared 12804.92% in 2021 and dropped 19.99% in 2023, its largest moves.
• Over 4 years, Finished Goods stood at $42922.4 in 2020, then surged by 12804.92% to $5.5 million in 2021, then surged by 48.51% to $8.2 million in 2022, then dropped by 19.99% to $6.6 million in 2023.
• The last three Finished Goods figures came in at $6.6 million (Q4 2023), $8.2 million (Q4 2022), and $5.5 million (Q4 2021), per Business Quant data.